Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Zev A. Wainberg, MD
Headshot of Zev A. Wainberg
Zev A. Wainberg

Description

Summary

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.

Official Title

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Keywords

Pancreatic Cancer, Cancer, Pancreatic Adenocarcinoma, Combination Therapy, CD39, Adenosine Pathway, Immunotherapy, Immuno-oncology, Pancreatic Ductal Adenocarcinoma, PD-1 Checkpoint Inhibitor, Budigalimab, TTX-030, metastatic, Paclitaxel, Albumin-Bound Paclitaxel, Gemcitabine, TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine

Eligibility

Locations

  • Investigative Site
    Los Angeles California 90095 United States
  • Investigative Site
    Fullerton California 92835 United States

Lead Scientist at UCLA

  • Zev A. Wainberg, MD
    Zev Wainberg, M.D., holds the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Trishula Therapeutics, Inc.
Links
Sign up for this study
ID
NCT06119217
Phase
Phase 2 Pancreatic Cancer Research Study
Study Type
Interventional
Participants
About 194 people participating
Last Updated